ovarian cancer, Johnson & Johnson

Ovarian cancer vaccines are under development, but none are ready for primetime. There are no screening tools for ovarian ...
Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.
The 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...
University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...
Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...
Ovarian cancer is the sixth most common cancer in women in the UK but the symptoms can be quite subtle, often leaving to a ...
It induces a specific type of immunity, called Th17 immunity, that seems to prevent suppression of the immune system. The ...
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...
A simple blood test could soon predict which ovarian cancer patients will stop responding to their treatment, paving the way ...
is effective and tolerable in heavily pre-treated patients with folate receptor alpha-positive (FRα+), platinum-sensitive ovarian cancer.
Multi-cancer Early Detection tests can screen for a variety of cancers that don't currently have annual screenings such as ...